DecisionX for CPG R&D
From first concept to the retail shelf and back, a new product moves through six stages, and unlike pharma's regulatory clock, CPG's constraint is the calendar itself: trend cycles, planogram resets, and seasonal windows that close on a fixed schedule whether or not the decision is ready. This is where DecisionX plugs in at each stage.
CPG NPD decision lifecycle
Six stages from Ideation to Post-launch, each shown as a gauge indicating relative severity of cost-of-delay, with Post-launch marked as recurring.
Stage by stage
Each stage below shows the decisions made, the data they run on, what DecisionX solves, and what it costs to get them wrong or make them late.
Before a single formula exists, someone decides which ideas are even worth funding: the highest-leverage, least-evidenced decision in the entire NPD lifecycle.
Ranks concepts and stage-gate proposals against each other for finite budget and lab capacity instead of letting seniority or habit decide what advances, and forecasts a project's odds of clearing the next gate against historical base rates instead of a champion's confidence.
Industry estimates commonly cite that the large majority of new CPG products fail within their first two years, and much of that failure traces back to weak concept screening: funding pursued the wrong idea before it ever reached a shelf.
Industry benchmarkA slow ideation-to-funding cycle hands white space to a faster competitor; category trend windows in CPG can close within a single retail planning cycle, so a delayed green-light can mean entering a trend after it has already peaked.
Industry benchmarkThe cheapest place to kill a bad idea: before formulation, tooling, and production spend turn a guess into a sunk cost.
Diagnoses whether early consumer signal is genuinely predictive or an artifact of a small, unrepresentative panel, and ranks candidate test markets or panels on true historical read-through instead of agency or research-firm relationships.
A concept that tests well on a biased panel but fails broadly can carry an under-validated product through full development spend before the real signal surfaces, commonly low-to-mid single-digit millions once formulation, packaging, and initial tooling are sunk.
Industry benchmarkConsumer and category trends move fast; a slow validation cycle risks validating a concept against a trend that has already shifted by the time development finishes.
Industry benchmarkUsually the longest phase in NPD, and where a hidden stability or spec problem is cheapest to catch: before tooling and production are committed.
Flags historically rework-prone formulation or packaging elements before spec lock, and simulates a candidate formulation or launch plan under shelf-life failure or supply disruption, locking a trigger-based response in advance instead of a reactive scramble.
A late-discovered stability failure or packaging defect after tooling is committed can force a costly rework or a full product recall. Recalls in food and CPG have run into the tens of millions in direct cost alone, before brand-trust impact.
Industry benchmarkEvery added month here compresses the runway to hit a fixed seasonal or retail-planogram launch window, and missing a planogram reset can mean waiting a full year for the next shelf opportunity.
Industry benchmarkEvery SKU refresh and every market variant needs its own verdict: high volume, high legal exposure, and CPG's closest structural cousin to pharma's regulatory case load.
Adjudicates whether a claim is substantiated and compliant before it goes on pack or in advertising, at the volume every SKU refresh and market variant requires, instead of ad hoc legal review that happens too late to change course.
A challenged or unsubstantiated claim can trigger legal action, mandatory relabeling, or a recall: regulatory and legal exposure that commonly runs into the millions, plus lasting brand-trust damage.
Industry benchmarkClaims review done late in the process is a common cause of launch-date slippage; a delayed compliance verdict can push a product past its intended seasonal window entirely.
Industry benchmarkThe hardest fixed constraint in the whole lifecycle: retail planogram resets happen once or twice a year, and there is no partial credit for being close.
Forecasts sell-in and trial-rate for the specific launch and commits production capacity and timeline against it, instead of anchoring to an optimistic aggregate, and flags which retailer/channel combinations are most likely to hit listing and shelf-reset windows.
Over-committing capacity against an optimistic launch forecast freezes working capital in unsold inventory; under-committing creates stockouts in the exact early weeks that determine a new product's long-term shelf survival.
Industry benchmarkRetail planogram resets happen on fixed, infrequent cycles, often once or twice a year per category; missing one can mean the product effectively cannot reach the shelf for another six to twelve months.
Industry benchmarkNot perpetual like pharma's safety clock, but recurring indefinitely: every cost spike, ingredient ban, or shortage restarts the same decision on a live, revenue-generating product.
Each time a trigger fires (a banned additive, a cost spike, a clean-label push, a supply shortage), adjudicates whether to reformulate, absorb the cost, or delay, and which substitute to commit to, replacing a fire-drill with a standing decision model; also diagnoses early whether underperformance signals a real decline or a distribution/measurement artifact before recommending discontinuation.
Rushed reformulation without a standing decision model has visibly damaged major brands' sales and consumer trust when a changed taste or quality was rejected; discontinuing a product that was actually a distribution issue, not a real decline, throws away a viable SKU.
Industry benchmarkA recurring trigger left unresolved, a soon-to-be-banned ingredient for example, can force an emergency reformulation under a hard regulatory deadline, with far less room to protect taste, cost, and quality than a decision made early.
Industry benchmarkThe System
Why a concept misfired, a claim was challenged, or sales declined.
Every stage-gate score and launch outcome sharpens the next ranking.
R&D, regulatory, and POS data reconciled before any ranking.
Decision AI for CPG R&D
See DecisionX on your pipeline, your claims, your launches. First value in 15 days.